Drug · CHEMBL894
BUPROPION
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BUPROPION. Drugs and targets, record CHEMBL894. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL894
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Amfebutamone, Bupropion extended release, Bupropion slow release, Bupropione, NSC-758686
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 40 diseases, from ATC and EMA Human Drugs
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6530 |
| SLC6A3 | Sodium-dependent dopamine transporter | Dopamine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6531 |
Source ChEMBL
Diseases40
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| nicotine dependence | Phase 3 | ClinicalTrials.gov | 52 | 52 | https://conductscience.org/library/drugs?q=MONDO_0008575 |
| major depressive disorder | Approval | ATC | 41 | 39 | https://conductscience.org/library/drugs?q=MONDO_0002009 |
| obesity disorder | Approval | EMA Human Drugs | 29 | 27 | https://conductscience.org/library/drugs?q=MONDO_0011122 |
| smoking cessation | Phase 3 | ClinicalTrials.gov | 23 | 23 | https://conductscience.org/library/drugs?q=EFO_0004319 |
| smoking behavior | Phase 3 | ClinicalTrials.gov | 16 | 16 | https://conductscience.org/library/drugs?q=EFO_0004318 |
| depressive disorder | Phase 3 | ClinicalTrials.gov and TTD | 11 | 10 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| methamphetamine dependence | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005419 |
| binge eating disorder | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005582 |
| bipolar disorder | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0004985 |
| attention deficit-hyperactivity disorder | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
1 to 10 of 40Source Open Targets
See all 40 diseasesTrials350
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 7 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01601704 | Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) | Phase 3 | 8,910 | 2017-02-27 | bupropion | Its name | ClinicalTrials.gov |
| NCT01456936 | Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders | Phase 4 | 8,144 | 2016-05-02 | bupropion | Its name | ClinicalTrials.gov |
| NCT01574703 | Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders. | Phase 4 | 4,595 | 2016-12-29 | bupropion | Its name | ClinicalTrials.gov |
| NCT00532779 | A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects | Phase 3 | 1,742 | 2014-11-21 | bupropion | Its name | ClinicalTrials.gov |
| NCT01421342 | VA Augmentation and Switching Treatments for Improving Depression Outcomes | Phase 3 | 1,522 | 2018-05-29 | bupropion | Its name | ClinicalTrials.gov |
| NCT00332644 | Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms | Phase 4 | 1,504 | 2011-11-30 | bupropion | Its name | ClinicalTrials.gov |
| NCT00567255 | A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects | Phase 3 | 1,496 | 2014-11-21 | bupropion | Its name | ClinicalTrials.gov |
| NCT00296647 | Smoking Cessation Intervention: Effectiveness in Primary Care | Phase 4 | 1,346 | 2011-11-30 | bupropion | Its name | ClinicalTrials.gov |
| NCT01023659 | Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts | Phase 4 | 893 | 2013-03-15 | bupropion | Its name | ClinicalTrials.gov |
| NCT04039022 | Open-Label Safety Study of AXS-05 in Subjects With Depression | Phase 3 | 876 | 2022-10-12 | bupropion | Its name | ClinicalTrials.gov |
1 to 10 of 350
See all 350 trialsComparisons in its trials172
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal) | 55 of 4,455 | 57 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke) | 17 of 4,455 | 34 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE) | 90 of 4,455 | 102 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal) | 22 of 4,455 | 21 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization | 133 of 4,455 | 142 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32 vs Placebo: serious adverse events | 463 of 4,455 | 386 of 4,450 | 8,905 | NCT01601704 | Trial comparisons |
| NB32/48 vs Placebo: serious adverse events | 21 of 992 | 7 of 492 | 1,484 | NCT00567255 | Trial comparisons |
| NB32 vs Placebo: serious adverse events | 22 of 584 | 1 of 200 | 784 | NCT00456521 | Trial comparisons |
| Varenicline and Buproprion SR vs Varenicline and Placebo: Prolonged Abstinence at 12 Months | 77 of 249 | 63 of 257 | 506 | NCT00935818 | Trial comparisons |
| Varenicline and Buproprion SR vs Varenicline and Placebo: Prolonged Smoking Abstinence Rates at 26 Weeks in Cigarettes Smokers. | 91 of 249 | 71 of 257 | 506 | NCT00935818 | Trial comparisons |
1 to 10 of 172
See all 172 comparisons in its trialsPapers from its trials418
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials19
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 4 | 0 | ConductCognition |
| Trail Making Test B | 4 | 0 | ConductCognition |
| Verbal Learning | 4 | 1 | ConductCognition |
| Effort for Rewards Task | 3 | 2 | ConductCognition |
| Continuous Performance Test | 2 | 0 | ConductCognition |
| Delay Discounting | 2 | 0 | ConductCognition |
| Effort Discounting Task | 2 | 0 | ConductCognition |
| Go/No-Go Task | 2 | 2 | ConductCognition |
| Monetary Incentive Delay | 2 | 2 | ConductCognition |
| Symbol Coding | 2 | 0 | ConductCognition |
1 to 10 of 19
See all 19 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL894
GET https://conductscience.org/api/drugs/v1/CHEMBL894/diseases?page=2